The largest community of pharma leaders

Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)

SAN LEANDRO, Calif.–(BUSINESS WIRE)–Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the first interim analysis results from its ongoing FIERCE-22 trial of vofatamab in patients with metastatic bladder cancer. Results were presented at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting. FIERCE-22 is a Phase 1b/2 trial evaluating vofatamab, a FGFR3-targeted antibody, in combination with pembrolizumab, an immune checkpoint…

 

http://www.businesswire.com/news/home/20190603005439/en/Rainier-Therapeutics-Announces-Results-Interim-Analysis-FIERCE-22/

Recent Articles

TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the positive...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.